Ventricular Assist Devices: Challenges of the One-device Era.
| Autor: | Moady G; Department of Cardiology, Galilee Medical Center Nahariya, Israel.; Azrieli Faculty of Medicine, Bar Ilan University Safed, Israel., Atar S; Department of Cardiology, Galilee Medical Center Nahariya, Israel.; Azrieli Faculty of Medicine, Bar Ilan University Safed, Israel., Ben-Avraham B; Department of Cardiology, Rabin Medical Center Petah Tikva, Israel.; Sackler Faculty of Medicine, Tel Aviv University Tel Aviv, Israel., Ben-Gal T; Department of Cardiology, Rabin Medical Center Petah Tikva, Israel.; Sackler Faculty of Medicine, Tel Aviv University Tel Aviv, Israel. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cardiac failure review [Card Fail Rev] 2022 Nov 18; Vol. 8, pp. e33. Date of Electronic Publication: 2022 Nov 18 (Print Publication: 2022). |
| DOI: | 10.15420/cfr.2022.01 |
| Abstrakt: | Heart failure (HF) is linked to to high mortality rates and recurrent hospitalisations despite medical and device-based achievements. The use of left ventricular assist devices (LVADs) has improved survival among patients with advanced HF. Significant progress has been achieved with the new generation of continuous-flow devices, particularly with the fully magnetically levitated HeartMate 3. In June 2021, Medtronic announced the abrupt withdrawal of the HeartWare device from the market. This decision has introduced a new era in which the field of mechanical support for advanced HF patients is dominated by a single device - the HeartMate 3. The direct clinical and economic consequences of this change will necessitate new surgical considerations. Because of the expected need for HeartWare device replacement in small patients, new surgical techniques and device adaptation will be needed. The new single-device era will hopefully encourage scientists and engineers to create innovations in the advanced HF arena. Special considerations should be taken during the COVID-19 pandemic when treating patients with LVADs. Competing Interests: Disclosure: The authors have no conflicts of interest to declare. (Copyright © 2022, Radcliffe Cardiology.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|